Grace Therapeutics, Inc.
GRCE
$4.44
-$0.01-0.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.33% | -8.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.16% | -18.16% | |||
| Operating Income | 3.16% | 18.16% | |||
| Income Before Tax | -146.80% | 72.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -146.80% | 72.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -146.80% | 72.10% | |||
| EBIT | 3.16% | 18.16% | |||
| EBITDA | 3.28% | 18.10% | |||
| EPS Basic | -132.09% | 72.10% | |||
| Normalized Basic EPS | -132.07% | 72.12% | |||
| EPS Diluted | -132.09% | 72.10% | |||
| Normalized Diluted EPS | -132.07% | 72.12% | |||
| Average Basic Shares Outstanding | 6.34% | 0.00% | |||
| Average Diluted Shares Outstanding | 6.34% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||